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Abstract
Randomized controlled trials (RCTs) represent the gold-standard of medical evidence to assess the effi-
cacy and safety of therapeutic interventions. However, the need to minimize bias and ensure the correct
design to explore the study aims often affects the generalizability of results. As a consequence, the
evidence derived from the most rigorous research strategy available is not always representative of the
real-world settings for which this evidence is ultimately intended. Observational studies, in contrast, al-
though affected by a number of potential confounders, can more effectively capture treatment character-
istics and safety issues that had not been identified by previous RCTs, owing to the short duration of
follow-up or highly selective inclusion criteria. The aim of this review is to provide a comparative summary
of the main advantages and pitfalls of RCTs and real-world data, emphasizing the need for a constant
integration of all available levels of evidence to provide the best care for patients.
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Rheumatology key messages
. Randomized controlled trials represent the best study design to assess efficacy of a therapeutic intervention.
. Results of randomized controlled trials often lack external validity (therefore generalizability) to the real-world population.
. Observational studies data need to be integrated, particularly to detect rare or late-onset adverse events.
Introduction
According to the principles of evidence-based medicine,
randomized controlled trials (RCTs) represent the corner-
stone of clinical research, providing the highest hierarch-
ical level of evidence based on a single experiment [1].
Randomized controlled trials are pivotal in the develop-
ment of new therapeutic strategies through the assess-
ment of the efficacy of new drugs vs placebo, or the
comparative performance against the standard of care.
Among the advantages, the unbiased distribution of
confounders, the minimized systematic differences in
treatment allocation and the application of blinded
procedures make RCTs the ideal study design in many
fields of research. Nevertheless, RCTs are not immune
to flaws. Indeed, in order to reduce the risk of bias, they
require strict inclusion and exclusion criteria, thus limiting
the generalizability of the findings to broader populations.
Large sample sizes are usually required, making RCTs
costly in terms of money and time. The high costs often
impose short trial durations, which may not cover the de-
tection of some rare or delayed side-effects and long-term
efficacy.
Real-world data have become particularly relevant in
filling some of the gaps left by data derived from the
highly selected populations enrolled in RCTs. The main
advantages of observational real-life studies are the
better representation of routine clinical practice scenarios,
the lower costs and the longer time of observation, thus
optimizing the detection of adverse events (AEs).
Observational data are extremely useful to improve the
management of rare conditions, particularly in those
cases still lacking generally recognized standards of
care. Nonetheless, the risk of bias is much higher with
observational studies. Although some statistical tools
help to minimize the effect of confounders, not all sources
of bias can be removed, making generalizability difficult to
achieve even with this type of study design. An overview
of the main differences between RCTs and observational
studies is presented in Table 1.
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In this review, we provide a comparative summary of
the advantages and drawbacks RCTs and real-world data
to promote a more critical interpretation of literature data,
taking into account the advantages and pitfalls connected
with the study design.
Patient selection criteria
Randomized controlled trials are designed to test the effects
of an intervention under ideal, controlled circumstances.
Strict adherence to protocols, application of inclusion
and exclusion criteria and patient randomization are all
essential steps to reduce the risk of bias. The results of
an RCT provide information regarding the expected effect
of the intervention in a well-defined population and in a
specific setting. The broader the population and the set-
tings, the greater is the external validity of the study,
which allows the conclusions to be generalized to routine
clinical practice. On the contrary, RCTs are designed to
maximize internal validity (which is the minimization of the
possibility of bias regarding the effect of an intervention) at
the expenses of generalizability [2].
As a result of strict selection criteria, patients enrolled in
RCTs are usually younger, with fewer co-morbidities and
shorter disease duration, and are therefore far from being
representative of the everyday clinical practice patient.
Therefore, the results of most RCTs, although strength-
ened by the rigorous methodology applied, do not allow
the same conclusions to be drawn automatically in a dif-
ferent population or setting.
A review on the external validity of RCTs in the fields of
cardiology, mental health and oncology found that a sig-
nificant proportion of the general population suffering with
those conditions would have not been included in RCTs,
thus being prescribed the intervention with no direct evi-
dence of the effects in that specific setting [3].
In the field of rheumatology, a clear example of the
difficulties in transferring evidence from RCTs to the real
world was demonstrated by Zink et al. [4] with the analysis
of the German biologics register Rheumatoid Arthritis
Observation of Biologic Therapy. The authors concluded
that only 33% of the patients treated in real life with a TNF
inhibitor (TNFi; infliximab, etanercept or adalimumab)
would have been eligible for the major trials that had led
to the approval of the drugs. Therefore, high-quality evi-
dence supporting the prescription of TNFi was lacking for
about two-thirds of RA patients included in the German
registry. Another example of this discrepancy was found
when applying the eligibility criteria of 30 RCTs on biolo-
gical drugs for RA to two observational clinical cohorts in
the USA: the Veterans Affairs Rheumatoid Arthritis registry
and the Rheumatology and Arthritis Investigational
Network Database [5]. The authors concluded that only
3.7% of patients in the Veterans Affairs Rheumatoid
Arthritis registry and 7.1% in the Rheumatology and
Arthritis Investigational Network Database would have
satisfied eligibility criteria for an RCT. Ineligibility was
mostly explained by lower disease activity in the observa-
tional cohorts in comparison with RCTs. These findings
can be explained, in part, by the design of RCTs used to
support regulatory approval of new treatment agents,
known as explanatory RTCs. Explanatory trials are speci-
fically developed to demonstrate treatment efficacy and
short-term safety. Typically, patients included in these
trials have significantly higher levels of disease activity
compared with clinical practice [5]. The other explanation,
once more, is the effect of restrictive eligibility criteria not
reflecting the characteristics of the everyday target popu-
lation. A possible solution to improve the extrapolation of
results to be applied in the routine care of patients with a
specific disease is to use a pragmatic RCT design. While
maintaining high internal validity, these trials more closely
reflect clinical practice, allowing for a higher degree of
heterogeneity of selected patients [6].
Efficacy and effectiveness
A relevant aspect that distinguishes data derived from
RCTs and observational studies is the difference between
efficacy and effectiveness of a specific intervention [7].
A treatment is effective when it produces the desired out-
come in ideal circumstances; therefore, in the context of
RCTs. Scientific evidence derived from RCTs clarifies
what the expected outcomes of a single treatment are
when offered to a well-defined population of patients
with selected features [8]. The experimental nature of
this process, including selection criteria, randomization
and blinding applied to researchers and subjects,
TABLE 1 Main strengths and weaknesses of randomized controlled trials compared with observational studies
Type of study Strengths Weaknesses
Randomized
clinical trials
Best for studying an intervention
Randomized
High internal validity
Unbiased distribution of confounders
Evaluates efficacy
Expensive: time and money
Short follow-up
Volunteer bias
Low generalizability to different or real-world
population
Observational
cohorts
(including
national
registries)
Best to study effects of risk factors on an
outcome
Participants can be matched
Detect rare or late-onset adverse events
Evaluate effectiveness
Channelling bias
Exposure may be linked to a hidden confounder
Blinding is difficult
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provides results in artificial settings, which may not be
fully extended to routine care. Consequently, most med-
ical treatments are used in real life on patients groups and
with doses and frequencies that have never been specif-
ically studied in the ideal conditions of RCTs. Indeed,
many patients assessed in routine care require multi-
drug treatments, with potential interactions, and may
have multiple conditions influencing the outcome.
Patients and disease characteristics may also differ sig-
nificantly from the counterparts enrolled in clinical trials.
These differences in the target population usually lead to
discrepancies between RCTs and the real-world esti-
mated magnitude of treatment effects [9].
Although the drug efficacy demonstrated by RCTs is not
put into question, the effectiveness, defined as the extent to
which a treatment achieves its intended effect in the usual
clinical practice, might have not been investigated suffi-
ciently before marketing approval. A treatment is effective
if it works in real life in non-ideal circumstances, which are
usually far from those observed in RCTs. To assess the ef-
fectiveness of a treatment, observational studies and real-
world data in general are superior to RCTs, allowing for
broader inclusion criteria and producing new evidence on
how the drug performs in realistic clinical conditions.
Observational studies ideally allow the inclusion of every
case treated with the intervention, providing data on its out-
comes in the complex environment of routine care.
In the case of RA, the effectiveness of treatments is usu-
ally lower when measured in real life compared with RCTs
[1012]. In particular, results from the Rheumatoid Arthritis
DMARD Intervention and Utilization Study indicated no
significant evidence of superiority in treating RA with
infliximab+MTX vs MTX alone when the treatment was
offered in routine clinical practice [12], in contrast to the
results of a previously conducted RCT [13]. This conflicting
evidence is explained by the difference in the study popu-
lations. Real-life patients often report higher lack of effi-
cacy, loss of efficacy and AE rates compared with RCT
patients. Possible explanations for this phenomenon are
the higher prevalence of co-morbidities, lower baseline
disease activity and lower adherence to treatment [14].
Although observational data are easily affected by bias,
lacking randomization and control for confounders, they
still represent the best available option to investigate the
therapeutic effect of the intervention in routine clinical
practice. Efficacy and effectiveness data should therefore
be integrated and interpreted in combination.
Safety
The assessment of safety is another key element that can
be influenced by the study design. In RCTs, small sam-
ples, strict patient selection criteria and short-term follow-
up do not always allow the measurement, with sufficient
statistical power, of the probability of rare AEs. Moreover,
AE rates recorded during RCTs do not precisely predict
the incidence of AEs in real-life settings. With the intent of
reducing the risk of bias, the population enrolled in RCTs
is selected with rigorous criteria and is blindly exposed to
the drug for a limited period of time. These limits may lead
to an incorrect estimate of the risk for the single AE, which
may result in an over- or underestimation. The latter was
the case in the risk for statin-induced myopathy: although
in RCTs 3% of patients developed myalgia, this condi-
tion was reported by 13% of the users in prospective clin-
ical studies [15]. The 4-fold increase in the prevalence
could result from several causes. The short duration of
RCTs might not have allowed the event to be detected
in patients who would have developed the AE after a
longer period of drug exposure; the selection criteria
might have excluded older patients and, possibly, other
categories with higher risk for myopathy; the frequency of
this AE reported from RCTs might have been lower by
chance, and the relatively small sample size might not
have allowed for a more precise estimate.
Another example of underestimation of risk in RCTs in
represented by hypoglycaemia event rates in patients with
type 1 diabetes mellitus and insulin-treated type 2 dia-
betes mellitus. A recent review compared the event
rates between RCTs and real-world data. Although a
large degree of overlap between the two settings existed,
hypoglycaemia was generally more frequent in real-world
populations [16]. The authors concluded that this differ-
ence might be explained by an underestimation of the
event in RCTs, which usually exclude some populations
with higher risk for hypoglycaemia, such as patients with
renal dysfunction, elderly frail patients or those with mal-
nutrition or co-morbidities. Moreover, patients enrolled in
RCTs are usually subjected to more intensive monitoring
than what is usually provided in routine clinical practice.
An example of risk overestimation is the issue of the
development of cancer in patients treated with TNFi.
When TNFi were prescribed to patients with RA for the
first time, the results of RCTs suggested an increase in
the risk of lymphoma [17, 18], and consequently, this AE
was reported on the product label. However, observational
real-world data derived from very large cohorts included in
several registries found no evidence of an increased risk
among patients assessed in routine clinical practice. The
apparently higher risk can be explained by the channelling
bias of treating those patients with the highest burden of
disease-related inflammation, and therefore an increased
risk of developing lymphoprolipherative disorders, with
TNFi. Therefore, the AE was not connected to the type of
treatment, but rather, it was associated with the charac-
teristics of the population [19, 20]. Likewise, another ex-
ample of AE well known to the rheumatological community
that had not emerged from the first RCTs in the early era of
TNFi use is the reactivation of latent tuberculosis [21].
Once more, these examples underline how the risk/bene-
fit ratio might be skewed if relying only on data from RCTs
and that there is a constant need to integrate all levels of
available evidence into the clinical management of patients.
Filling the gap between RCTs and real-
world data
The issue of generalizability and extrapolation of the re-
sults of RCTs to the routine care of patients is a problem
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that affects all medical disciplines. Results of RCTs are
essential to inform international recommendations for
specific conditions and to widen the therapeutic arma-
mentarium. Nevertheless, continuous real-world data sur-
veillance and analysis needs to be carried out to fill the
efficacyeffectiveness gap and to capture fully the long-
term safety of drugs when applied to the imperfect routine
care patient. As advocated in the previous sections of this
review, the treating clinician needs to combine all the
available evidence, keeping in mind the advantages and
limits related to the study design. Future research should
be improved by a better integration of RCTs and obser-
vational studies, by applying selection criteria that better
reflect the real-life target populations. Moreover, evidence
synthesis tools should be implemented to offer a more
critical point of view by combining all levels of available
scientific evidence. Some of these tools are already well
known. Meta-analyses offer the advantage of combining
the results of several studies, increasing the sample size
and the power of the results obtained. Another strategy
that can be applied to improve the usability of the results
obtained is to adapt the trial design according to its
scope. Pragmatic RCTs can better reflect the conditions
of routine practice. Adaptive trials can be adjusted in
response to information generated during the trial, while
n-of-1 trials or single subject clinical trials focus on indivi-
dualized treatment strategies in the setting of high popu-
lation heterogeneity [22].
Furthermore, in recent years, more structured efforts
are being directed towards finding a way of providing
scientific data with a high level of evidence, while being
more applicable to the real target populations. The prag-
matic-explanatory continuum indicator summary tool has
been developed to allow trialists to design studies that
better match with the needs of the intended users of the
study results. Finally, this tool can also be used to assess
the methodological quality of completed trials [3].
Conclusions
Randomized controlled trials remain the gold standard to
assess the efficacy of an intervention. They are irreplace-
able when the effect of a new treatment needs to be
tested. Observational data can provide valuable evidence
from real-life routine clinical care and identify previously
unrecognized aspects related to treatment characteristics
and safety.
All study designs, taking into account specific strengths
and limitations, should contribute to generate the scien-
tific evidence that will guide the real evidence-based ap-
proach to the patient.
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